| sodium channel, voltage-gated, type I, beta |
QUETIAPINE |
Sodium Channel, Site 2 |
45% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type I, alpha |
QUETIAPINE |
Sodium Channel, Site 2 |
45% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type IV, beta |
QUETIAPINE |
Sodium Channel, Site 2 |
45% |
NoneNone |
NoneNone |
View
|
| sodium channel associated protein 1 |
QUETIAPINE |
Sodium Channel, Site 2 |
45% |
NoneNone |
NoneNone |
View
|
| sodium channel associated protein 2 |
QUETIAPINE |
Sodium Channel, Site 2 |
45% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type III, beta |
QUETIAPINE |
Sodium Channel, Site 2 |
45% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type I, alpha |
QUETIAPINE |
Sodium Channel, Site 2 |
45% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type IX, alpha |
QUETIAPINE |
Sodium Channel, Site 2 |
45% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type VII, alpha |
QUETIAPINE |
Sodium Channel, Site 2 |
45% |
NoneNone |
NoneNone |
View
|
| amiloride-sensitive cation channel 5, intestinal |
QUETIAPINE |
Sodium Channel, Site 2 |
45% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type III, beta |
QUETIAPINE |
Sodium Channel, Site 2 |
45% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type VIII, alpha polypeptide |
QUETIAPINE |
Sodium Channel, Site 2 |
45% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type XI, alpha |
QUETIAPINE |
Sodium Channel, Site 2 |
45% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type I, beta |
QUETIAPINE |
Sodium Channel, Site 2 |
45% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type 10, alpha polypeptide |
QUETIAPINE |
Sodium Channel, Site 2 |
45% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type IV, alpha polypeptide |
QUETIAPINE |
Sodium Channel, Site 2 |
45% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type V, alpha polypeptide |
QUETIAPINE |
Sodium Channel, Site 2 |
45% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type II, beta |
QUETIAPINE |
Sodium Channel, Site 2 |
45% |
NoneNone |
NoneNone |
View
|
| sodium channel, nonvoltage-gated 1 alpha |
QUETIAPINE |
Sodium Channel, Site 2 |
45% |
NoneNone |
NoneNone |
View
|
| sodium channel, nonvoltage-gated 1 gamma |
QUETIAPINE |
Sodium Channel, Site 2 |
45% |
NoneNone |
NoneNone |
View
|
| sodium channel, nonvoltage-gated 1 beta |
QUETIAPINE |
Sodium Channel, Site 2 |
45% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type 2, alpha 1 polypeptide |
QUETIAPINE |
Sodium Channel, Site 2 |
45% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type XI, alpha |
QUETIAPINE |
Sodium Channel, Site 2 |
45% |
NoneNone |
NoneNone |
View
|
| sodium channel, nonvoltage-gated 1, gamma |
QUETIAPINE |
Sodium Channel, Site 2 |
45% |
NoneNone |
NoneNone |
View
|
| sodium channel, nonvoltage-gated 1, delta |
QUETIAPINE |
Sodium Channel, Site 2 |
45% |
NoneNone |
NoneNone |
View
|
| sodium channel, nonvoltage-gated 1, beta (Liddle syndrome) |
QUETIAPINE |
Sodium Channel, Site 2 |
45% |
NoneNone |
NoneNone |
View
|
| sodium channel, nonvoltage-gated 1 alpha |
QUETIAPINE |
Sodium Channel, Site 2 |
45% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type X, alpha |
QUETIAPINE |
Sodium Channel, Site 2 |
45% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type IX, alpha |
QUETIAPINE |
Sodium Channel, Site 2 |
45% |
NoneNone |
NoneNone |
View
|
| solute carrier family 28 (sodium-coupled nucleoside transporter), member 3 |
IMATINIB |
Adenosine Transporter |
45% |
NoneNone |
NoneNone |
View
|
| concentrative Na+ nucleoside cotransporter (DBSS) |
IMATINIB |
Adenosine Transporter |
45% |
NoneNone |
NoneNone |
View
|
| solute carrier family 28 (sodium-coupled nucleoside transporter), member 1 |
IMATINIB |
Adenosine Transporter |
45% |
NoneNone |
NoneNone |
View
|
| adenine nucleotide translocase (DBSS) (Non-specific probe) |
IMATINIB |
Adenosine Transporter |
45% |
NoneNone |
NoneNone |
View
|
| solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 4 |
IMATINIB |
Adenosine Transporter |
45% |
NoneNone |
NoneNone |
View
|
| v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) |
3-METHYLCHOLANTHRENE |
Protein Tyrosine Kinase, HER2 Receptor |
48% |
NoneNone |
NoneNone |
View
|
| adrenergic receptor, alpha 1a |
U-78517F |
Adrenergic alpha1A |
48% |
NoneNone |
NoneNone |
View
|
| estrogen receptor 1 |
CLOTRIMAZOLE |
Estrogen ERalpha |
48% |
NoneNone |
NoneNone |
View
|
| estrogen receptor 1 |
CLOTRIMAZOLE |
Estrogen ERalpha |
48% |
NoneNone |
NoneNone |
View
|
| mitogen activated protein kinase 14 |
TRETINOIN |
Protein Serine/Threonine Kinase, p38alpha |
48% |
NoneNone |
NoneNone |
View
|
| mitogen-activated protein kinase 14 |
TRETINOIN |
Protein Serine/Threonine Kinase, p38alpha |
48% |
NoneNone |
NoneNone |
View
|
| Cytochrom P450-1A2 monooxygenase |
DIHYDROERGOTAMINE |
CYP450-1A2 Inhibition |
48% |
NoneNone |
NoneNone |
View
|
| cytochrome P450, family 3, subfamily a, polypeptide 13 |
PRALIDOXIME CHLORIDE |
CYP450-3A4 Inhibition |
48% |
NoneNone |
NoneNone |
View
|
| potassium voltage-gated channel, subfamily H (eag-related), member 3 |
CYPROHEPTADINE |
Potassium Channel HERG |
48% |
17.0491uM |
13.9679uM |
View
|
| potassium voltage-gated channel, subfamily H (eag-related), member 4 |
CYPROHEPTADINE |
Potassium Channel HERG |
48% |
17.0491uM |
13.9679uM |
View
|
| potassium voltage-gated channel, subfamily H (eag-related), member 1 |
CYPROHEPTADINE |
Potassium Channel HERG |
48% |
17.0491uM |
13.9679uM |
View
|
| potassium voltage-gated channel, subfamily H (eag-related), member 1 |
CYPROHEPTADINE |
Potassium Channel HERG |
48% |
17.0491uM |
13.9679uM |
View
|
| potassium voltage-gated channel, subfamily H, member 8 |
CYPROHEPTADINE |
Potassium Channel HERG |
48% |
17.0491uM |
13.9679uM |
View
|
| potassium voltage-gated channel, subfamily H (eag-related), member 6 |
CYPROHEPTADINE |
Potassium Channel HERG |
48% |
17.0491uM |
13.9679uM |
View
|
| potassium voltage-gated channel, subfamily H (eag-related), member 7 |
CYPROHEPTADINE |
Potassium Channel HERG |
48% |
17.0491uM |
13.9679uM |
View
|
| potassium voltage-gated channel, subfamily H (eag-related), member 2 |
CYPROHEPTADINE |
Potassium Channel HERG |
48% |
17.0491uM |
13.9679uM |
View
|
| potassium voltage-gated channel, subfamily H (eag-related), member 5 |
CYPROHEPTADINE |
Potassium Channel HERG |
48% |
17.0491uM |
13.9679uM |
View
|
| Cytochrom P450-2C19 monooxygenase |
BW-723C86 |
CYP450-2C19 Inhibition |
48% |
NoneNone |
NoneNone |
View
|
| 5-hydroxytryptamine (serotonin) receptor 1A |
HEXACHLOROPHENE |
Serotonin 5-HT1A |
48% |
NoneNone |
NoneNone |
View
|
| A3 adenosine receptor |
PERHEXILINE |
Adenosine A3 |
48% |
NoneNone |
NoneNone |
View
|
| opioid receptor, sigma 1 |
DESLORATADINE |
Sigma1 |
48% |
NoneNone |
NoneNone |
View
|
| 5-hydroxytryptamine (serotonin) receptor 2B |
4-NONYLPHENOL |
Serotonin 5-HT2B |
48% |
NoneNone |
NoneNone |
View
|
| mitogen activated protein kinase 1 |
FLUNOXAPROFEN |
Protein Serine/Threonine Kinase, ERK2 |
48% |
NoneNone |
NoneNone |
View
|
| mitogen-activated protein kinase 1 |
FLUNOXAPROFEN |
Protein Serine/Threonine Kinase, ERK2 |
48% |
NoneNone |
NoneNone |
View
|
| cholinergic receptor, muscarinic 1 |
HYDROXYCHLOROQUINE |
Muscarinic M1 |
48% |
NoneNone |
NoneNone |
View
|
| histamine receptor H 2 |
CYCLIZINE |
Histamine H2 |
48% |
NoneNone |
NoneNone |
View
|
| Cytochrom P450-2D6 monooxygenase |
MOXONIDINE |
CYP450-2D6 Inhibition |
48% |
NoneNone |
NoneNone |
View
|
| Cytochrom P450-2D6 monooxygenase |
VECURONIUM BROMIDE |
CYP450-2D6 Inhibition |
48% |
NoneNone |
NoneNone |
View
|
| Cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase) |
EBASTINE |
CYP450-2C9 Inhibition |
48% |
NoneNone |
NoneNone |
View
|
| cytochrome P450, family 2, subfamily C, polypeptide 9 |
EBASTINE |
CYP450-2C9 Inhibition |
48% |
NoneNone |
NoneNone |
View
|
| Cytochrom P450-2D6 monooxygenase |
GUANABENZ |
CYP450-2D6 Inhibition |
48% |
NoneNone |
NoneNone |
View
|
| Cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase) |
FLUORESCEIN |
CYP450-2C9 Inhibition |
48% |
NoneNone |
NoneNone |
View
|
| cytochrome P450, family 2, subfamily C, polypeptide 9 |
FLUORESCEIN |
CYP450-2C9 Inhibition |
48% |
NoneNone |
NoneNone |
View
|
| acetylcholinesterase (YT blood group) |
CINNARIZINE |
Acetylcholinesterase |
48% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type III, beta |
PUROMYCIN |
Sodium Channel, Site 2 |
12% |
NoneNone |
NoneNone |
View
|
| collagen-like tail subunit (single strand of homotrimer) of asymmetric acetylcholinesterase |
CINNARIZINE |
Acetylcholinesterase |
48% |
NoneNone |
NoneNone |
View
|
| acetylcholinesterase |
CINNARIZINE |
Acetylcholinesterase |
48% |
NoneNone |
NoneNone |
View
|
| cathepsin G |
3,3',4',5-TETRACHLOROSALICYLANILIDE |
Protease, Cathepsin G |
48% |
NoneNone |
NoneNone |
View
|
| mast cell protease 9 |
3,3',4',5-TETRACHLOROSALICYLANILIDE |
Protease, Cathepsin G |
48% |
NoneNone |
NoneNone |
View
|
| epidermal growth factor receptor |
FENBENDAZOLE |
Protein Tyrosine Kinase, EGF Receptor |
48% |
NoneNone |
NoneNone |
View
|
| leukotriene B4 receptor 2 |
CLOSANTEL |
Leukotriene B4 |
48% |
NoneNone |
NoneNone |
View
|
| leukotriene B4 receptor |
CLOSANTEL |
Leukotriene B4 |
48% |
NoneNone |
NoneNone |
View
|
| leukotriene B4 receptor |
CLOSANTEL |
Leukotriene B4 |
48% |
NoneNone |
NoneNone |
View
|
| leukotriene B4 receptor 2 |
CLOSANTEL |
Leukotriene B4 |
48% |
NoneNone |
NoneNone |
View
|
| adrenergic receptor, alpha 2a |
GRAMICIDIN |
Adrenergic alpha2A |
48% |
NoneNone |
NoneNone |
View
|
| solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 |
GRAMICIDIN |
Dopamine Transporter |
48% |
NoneNone |
NoneNone |
View
|
| androgen receptor |
GRAMICIDIN |
Testosterone |
48% |
NoneNone |
NoneNone |
View
|
| neuropeptide Y receptor Y2 |
DIGITONIN |
Neuropeptide Y2 |
48% |
NoneNone |
NoneNone |
View
|
| neuropeptide Y receptor Y2 |
DIGITONIN |
Neuropeptide Y2 |
48% |
NoneNone |
NoneNone |
View
|
| solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 |
ABAMECTIN |
Dopamine Transporter |
48% |
NoneNone |
NoneNone |
View
|
| solute carrier family 28 (sodium-coupled nucleoside transporter), member 3 |
ERGOTAMINE |
Adenosine Transporter |
48% |
NoneNone |
NoneNone |
View
|
| concentrative Na+ nucleoside cotransporter (DBSS) |
ERGOTAMINE |
Adenosine Transporter |
48% |
NoneNone |
NoneNone |
View
|
| solute carrier family 28 (sodium-coupled nucleoside transporter), member 1 |
ERGOTAMINE |
Adenosine Transporter |
48% |
NoneNone |
NoneNone |
View
|
| adenine nucleotide translocase (DBSS) (Non-specific probe) |
ERGOTAMINE |
Adenosine Transporter |
48% |
NoneNone |
NoneNone |
View
|
| solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 4 |
ERGOTAMINE |
Adenosine Transporter |
48% |
NoneNone |
NoneNone |
View
|
| v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) |
ERGOTAMINE |
Protein Tyrosine Kinase, HER2 Receptor |
48% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type VIII, alpha polypeptide |
CETYLPYRIDINIUM BROMIDE |
Sodium Channel, Site 2 |
46% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type XI, alpha |
CETYLPYRIDINIUM BROMIDE |
Sodium Channel, Site 2 |
46% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type I, beta |
CETYLPYRIDINIUM BROMIDE |
Sodium Channel, Site 2 |
46% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type 10, alpha polypeptide |
CETYLPYRIDINIUM BROMIDE |
Sodium Channel, Site 2 |
46% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type IV, alpha polypeptide |
CETYLPYRIDINIUM BROMIDE |
Sodium Channel, Site 2 |
46% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type V, alpha polypeptide |
CETYLPYRIDINIUM BROMIDE |
Sodium Channel, Site 2 |
46% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type II, beta |
CETYLPYRIDINIUM BROMIDE |
Sodium Channel, Site 2 |
46% |
NoneNone |
NoneNone |
View
|
| sodium channel, nonvoltage-gated 1 alpha |
CETYLPYRIDINIUM BROMIDE |
Sodium Channel, Site 2 |
46% |
NoneNone |
NoneNone |
View
|
| sodium channel, nonvoltage-gated 1 gamma |
CETYLPYRIDINIUM BROMIDE |
Sodium Channel, Site 2 |
46% |
NoneNone |
NoneNone |
View
|
| sodium channel, nonvoltage-gated 1 beta |
CETYLPYRIDINIUM BROMIDE |
Sodium Channel, Site 2 |
46% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type 2, alpha 1 polypeptide |
CETYLPYRIDINIUM BROMIDE |
Sodium Channel, Site 2 |
46% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type XI, alpha |
CETYLPYRIDINIUM BROMIDE |
Sodium Channel, Site 2 |
46% |
NoneNone |
NoneNone |
View
|
| sodium channel, nonvoltage-gated 1, gamma |
CETYLPYRIDINIUM BROMIDE |
Sodium Channel, Site 2 |
46% |
NoneNone |
NoneNone |
View
|
| sodium channel, nonvoltage-gated 1, delta |
CETYLPYRIDINIUM BROMIDE |
Sodium Channel, Site 2 |
46% |
NoneNone |
NoneNone |
View
|
| sodium channel, nonvoltage-gated 1, beta (Liddle syndrome) |
CETYLPYRIDINIUM BROMIDE |
Sodium Channel, Site 2 |
46% |
NoneNone |
NoneNone |
View
|
| sodium channel, nonvoltage-gated 1 alpha |
CETYLPYRIDINIUM BROMIDE |
Sodium Channel, Site 2 |
46% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type X, alpha |
CETYLPYRIDINIUM BROMIDE |
Sodium Channel, Site 2 |
46% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type IX, alpha |
CETYLPYRIDINIUM BROMIDE |
Sodium Channel, Site 2 |
46% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage gated, type VIII, alpha |
CETYLPYRIDINIUM BROMIDE |
Sodium Channel, Site 2 |
46% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type VII, alpha |
CETYLPYRIDINIUM BROMIDE |
Sodium Channel, Site 2 |
46% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type V, alpha (long QT syndrome 3) |
CETYLPYRIDINIUM BROMIDE |
Sodium Channel, Site 2 |
46% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type IV, beta |
CETYLPYRIDINIUM BROMIDE |
Sodium Channel, Site 2 |
46% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type IV, alpha |
CETYLPYRIDINIUM BROMIDE |
Sodium Channel, Site 2 |
46% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type III, alpha |
CETYLPYRIDINIUM BROMIDE |
Sodium Channel, Site 2 |
46% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type II, beta |
CETYLPYRIDINIUM BROMIDE |
Sodium Channel, Site 2 |
46% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type II, alpha 2 |
CETYLPYRIDINIUM BROMIDE |
Sodium Channel, Site 2 |
46% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type I, beta |
CETYLPYRIDINIUM BROMIDE |
Sodium Channel, Site 2 |
46% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type I, alpha |
CETYLPYRIDINIUM BROMIDE |
Sodium Channel, Site 2 |
46% |
NoneNone |
NoneNone |
View
|
| histamine receptor H 1 |
RALOXIFENE |
Histamine H1, Central |
46% |
NoneNone |
NoneNone |
View
|
| Protein-tyrosine kinase, Fyn |
SB-203580 |
Protein Tyrosine Kinase, Fyn |
46% |
NoneNone |
NoneNone |
View
|
| thromboxane A synthase 1 |
ASTEMIZOLE |
Thromboxane Synthetase |
46% |
NoneNone |
NoneNone |
View
|
| thromboxane A synthase 1 (platelet, cytochrome P450, family 5, subfamily A) |
ASTEMIZOLE |
Thromboxane Synthetase |
46% |
NoneNone |
NoneNone |
View
|
| 5-hydroxytryptamine (serotonin) receptor 1A |
CLOMIPHENE |
Serotonin 5-HT1A |
46% |
NoneNone |
NoneNone |
View
|
| cholinergic receptor, muscarinic 1 |
DROPERIDOL |
Muscarinic M1 |
46% |
NoneNone |
NoneNone |
View
|
| cholinergic receptor, muscarinic 4 |
PIPAMAZINE |
Muscarinic M4 |
46% |
NoneNone |
NoneNone |
View
|
| angiotensin II receptor, type 2 |
RAMIPRIL |
Angiotensin AT2 |
46% |
NoneNone |
NoneNone |
View
|
| thromboxane A synthase 1 |
LOPERAMIDE |
Thromboxane Synthetase |
46% |
NoneNone |
NoneNone |
View
|
| thromboxane A synthase 1 (platelet, cytochrome P450, family 5, subfamily A) |
LOPERAMIDE |
Thromboxane Synthetase |
46% |
NoneNone |
NoneNone |
View
|
| 5-hydroxytryptamine (serotonin) receptor 2C |
MEXILETINE |
Serotonin 5-HT2C |
46% |
NoneNone |
NoneNone |
View
|
| lymphocyte protein tyrosine kinase (mapped) |
RWJ-68354 |
Protein Tyrosine Kinase, Lck |
46% |
NoneNone |
NoneNone |
View
|
| solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 |
4-(PHENYLMETHYL)-1-[2-(TRIFLUOROMETHYL)BENZOYL]-PIPERIDINE |
Dopamine Transporter |
46% |
NoneNone |
NoneNone |
View
|
| solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 |
N,N'-DIPHENYL-P-PHENYLENEDIAMINE |
Dopamine Transporter |
46% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type IV, beta |
IMIQUIMOD |
Sodium Channel, Site 2 |
46% |
NoneNone |
NoneNone |
View
|
| sodium channel associated protein 1 |
IMIQUIMOD |
Sodium Channel, Site 2 |
46% |
NoneNone |
NoneNone |
View
|
| sodium channel associated protein 2 |
IMIQUIMOD |
Sodium Channel, Site 2 |
46% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type III, beta |
IMIQUIMOD |
Sodium Channel, Site 2 |
46% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type I, alpha |
IMIQUIMOD |
Sodium Channel, Site 2 |
46% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type IX, alpha |
IMIQUIMOD |
Sodium Channel, Site 2 |
46% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type VII, alpha |
IMIQUIMOD |
Sodium Channel, Site 2 |
46% |
NoneNone |
NoneNone |
View
|
| amiloride-sensitive cation channel 5, intestinal |
IMIQUIMOD |
Sodium Channel, Site 2 |
46% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type III, beta |
IMIQUIMOD |
Sodium Channel, Site 2 |
46% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type VIII, alpha polypeptide |
IMIQUIMOD |
Sodium Channel, Site 2 |
46% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type XI, alpha |
IMIQUIMOD |
Sodium Channel, Site 2 |
46% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type I, beta |
IMIQUIMOD |
Sodium Channel, Site 2 |
46% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type 10, alpha polypeptide |
IMIQUIMOD |
Sodium Channel, Site 2 |
46% |
NoneNone |
NoneNone |
View
|
| adrenergic receptor, alpha 2b |
NELFINAVIR |
Adrenergic alpha2C |
45% |
NoneNone |
NoneNone |
View
|
| adrenergic receptor, alpha 2c (Non-specific probe) |
NELFINAVIR |
Adrenergic alpha2C |
45% |
NoneNone |
NoneNone |
View
|
| dopamine receptor D3 |
PYRILAMINE |
Dopamine D3 |
45% |
NoneNone |
NoneNone |
View
|
| adrenergic receptor, alpha 1a |
PAROXETINE |
Adrenergic alpha1A |
45% |
NoneNone |
NoneNone |
View
|
| Cytochrom P450-2C19 monooxygenase |
VX-745 |
CYP450-2C19 Inhibition |
45% |
NoneNone |
NoneNone |
View
|
| Cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase) |
VX-745 |
CYP450-2C9 Inhibition |
45% |
NoneNone |
NoneNone |
View
|
| cytochrome P450, family 2, subfamily C, polypeptide 9 |
VX-745 |
CYP450-2C9 Inhibition |
45% |
NoneNone |
NoneNone |
View
|
| epidermal growth factor receptor |
TERCONAZOLE |
Protein Tyrosine Kinase, EGF Receptor |
45% |
NoneNone |
NoneNone |
View
|
| 5-hydroxytryptamine (serotonin) receptor 1B |
TERBINAFINE |
Serotonin 5-HT1B |
45% |
NoneNone |
NoneNone |
View
|
| chemokine (C-C motif) receptor 2 |
STANOLONE |
Chemokine CCR2B |
45% |
NoneNone |
NoneNone |
View
|
| cholinergic receptor, muscarinic 4 |
TACRINE |
Muscarinic M4 |
45% |
NoneNone |
NoneNone |
View
|
| mitogen activated protein kinase 1 |
ROSIGLITAZONE |
Protein Serine/Threonine Kinase, ERK2 |
45% |
NoneNone |
NoneNone |
View
|
| mitogen-activated protein kinase 1 |
ROSIGLITAZONE |
Protein Serine/Threonine Kinase, ERK2 |
45% |
NoneNone |
NoneNone |
View
|
| adrenergic receptor, alpha 2a |
PRILOCAINE |
Imidazoline I2, Central |
45% |
NoneNone |
NoneNone |
View
|
| adrenergic receptor, alpha 2c (Non-specific probe) |
PRILOCAINE |
Imidazoline I2, Central |
45% |
NoneNone |
NoneNone |
View
|
| histamine receptor H 2 |
PIOGLITAZONE |
Histamine H2 |
45% |
NoneNone |
NoneNone |
View
|
| adrenergic receptor, alpha 2b |
1,3-DIPHENYLGUANIDINE |
Adrenergic alpha2B |
45% |
NoneNone |
NoneNone |
View
|
| adrenergic receptor, alpha 2a |
PINDOLOL |
Adrenergic alpha2A |
45% |
NoneNone |
NoneNone |
View
|
| 5-hydroxytryptamine (serotonin) receptor 1B |
PINDOLOL |
Serotonin 5-HT1B |
45% |
NoneNone |
NoneNone |
View
|
| sodium channel, voltage-gated, type 10, alpha polypeptide |
GW-1929 |
Sodium Channel, Site 2 |
45% |
NoneNone |
NoneNone |
View
|
| potassium voltage-gated channel, subfamily H, member 8 |
CITALOPRAM |
Potassium Channel HERG |
45% |
16.6754uM |
13.6618uM |
View
|
| potassium voltage-gated channel, subfamily H (eag-related), member 6 |
CITALOPRAM |
Potassium Channel HERG |
45% |
16.6754uM |
13.6618uM |
View
|
| potassium voltage-gated channel, subfamily H (eag-related), member 7 |
CITALOPRAM |
Potassium Channel HERG |
45% |
16.6754uM |
13.6618uM |
View
|
| potassium voltage-gated channel, subfamily H (eag-related), member 2 |
CITALOPRAM |
Potassium Channel HERG |
45% |
16.6754uM |
13.6618uM |
View
|
| potassium voltage-gated channel, subfamily H (eag-related), member 5 |
CITALOPRAM |
Potassium Channel HERG |
45% |
16.6754uM |
13.6618uM |
View
|
| potassium voltage-gated channel, subfamily H (eag-related), member 3 |
CITALOPRAM |
Potassium Channel HERG |
45% |
16.6754uM |
13.6618uM |
View
|
| potassium voltage-gated channel, subfamily H (eag-related), member 4 |
CITALOPRAM |
Potassium Channel HERG |
45% |
16.6754uM |
13.6618uM |
View
|
| potassium voltage-gated channel, subfamily H (eag-related), member 1 |
CITALOPRAM |
Potassium Channel HERG |
45% |
16.6754uM |
13.6618uM |
View
|
| potassium voltage-gated channel, subfamily H (eag-related), member 1 |
CITALOPRAM |
Potassium Channel HERG |
45% |
16.6754uM |
13.6618uM |
View
|
| cholinergic receptor, muscarinic 2 |
TRANS-PLATINUM(II)DIAMMINE DICHLORIDE |
Muscarinic M2 |
45% |
NoneNone |
NoneNone |
View
|
| histamine receptor H 1 |
PERHEXILINE |
Histamine H1, Central |
45% |
NoneNone |
NoneNone |
View
|
| tachykinin receptor 2 |
PERHEXILINE |
Tachykinin NK2 |
45% |
NoneNone |
NoneNone |
View
|
| melanocortin 5 receptor |
PERHEXILINE |
Melanocortin MC5 |
45% |
NoneNone |
NoneNone |
View
|
| endothelin receptor type A |
PERHEXILINE |
Endothelin ETA |
45% |
NoneNone |
NoneNone |
View
|
| Sigma-2 Receptor |
IMATINIB |
Sigma2 |
45% |
NoneNone |
NoneNone |
View
|
| cholinergic receptor, muscarinic 4 |
HYDROXYCHLOROQUINE |
Muscarinic M4 |
45% |
NoneNone |
NoneNone |
View
|
| adrenergic receptor, alpha 2a |
DOMPERIDONE |
Imidazoline I2, Central |
45% |
NoneNone |
NoneNone |
View
|
| adrenergic receptor, alpha 2c (Non-specific probe) |
DOMPERIDONE |
Imidazoline I2, Central |
45% |
NoneNone |
NoneNone |
View
|
| adrenergic receptor, alpha 2a |
FLUNARIZINE |
Imidazoline I2, Central |
45% |
NoneNone |
NoneNone |
View
|
| adrenergic receptor, alpha 2c (Non-specific probe) |
FLUNARIZINE |
Imidazoline I2, Central |
45% |
NoneNone |
NoneNone |
View
|
| histamine receptor H 2 |
CINNARIZINE |
Histamine H2 |
45% |
NoneNone |
NoneNone |
View
|
| dopamine receptor D3 |
DIMENHYDRINATE |
Dopamine D3 |
45% |
NoneNone |
NoneNone |
View
|
| dopamine receptor D1A |
CYCLIZINE |
Dopamine D1 |
45% |
NoneNone |
NoneNone |
View
|
| prostaglandin-endoperoxide synthase 2 |
ZAFIRLUKAST |
Cyclooxygenase COX-2 |
45% |
NoneNone |
NoneNone |
View
|
| prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) |
ZAFIRLUKAST |
Cyclooxygenase COX-2 |
45% |
NoneNone |
NoneNone |
View
|
| cytochrome P450, family 3, subfamily a, polypeptide 13 |
DOXAPRAM |
CYP450-3A4 Inhibition |
45% |
NoneNone |
NoneNone |
View
|
| Cytochrom P450-2D6 monooxygenase |
SPIRONOLACTONE |
CYP450-2D6 Inhibition |
45% |
NoneNone |
NoneNone |
View
|
| Cytochrom P450-2D6 monooxygenase |
METHYSERGIDE |
CYP450-2D6 Inhibition |
45% |
NoneNone |
NoneNone |
View
|
| Cytochrom P450-2C19 monooxygenase |
CILOSTAZOL |
CYP450-2C19 Inhibition |
45% |
NoneNone |
NoneNone |
View
|
| cholinergic receptor, muscarinic 4 |
BERBERINE CHLORIDE |
Muscarinic M4 |
45% |
NoneNone |
NoneNone |
View
|
| caspase 1 |
RIFAPENTINE |
Protease, Caspase 1 |
45% |
NoneNone |
NoneNone |
View
|
| caspase 1, apoptosis-related cysteine protease (interleukin 1, beta, convertase) |
RIFAPENTINE |
Protease, Caspase 1 |
45% |
NoneNone |
NoneNone |
View
|
| caspase 3, apoptosis related cysteine protease |
RIFAPENTINE |
Protease, Caspase 1 |
45% |
NoneNone |
NoneNone |
View
|
| caspase 2 |
RIFAPENTINE |
Protease, Caspase 1 |
45% |
NoneNone |
NoneNone |
View
|
| caspase 7 |
RIFAPENTINE |
Protease, Caspase 1 |
45% |
NoneNone |
NoneNone |
View
|